Screener
Celldex Therapeutics CLDX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's total equity?
- Celldex Therapeutics (CLDX) reported total equity of $714.56M in Q2 2026.
- How has Celldex Therapeutics's total equity changed year-over-year?
- Celldex Therapeutics's total equity increased by 9.0% year-over-year, from $655.41M to $714.56M.
- What is the long-term trend for Celldex Therapeutics's total equity?
- Over 5 years (2020 to 2025), Celldex Therapeutics's total equity has grown at a 20.3% compound annual growth rate (CAGR), from $209.36M to $527.17M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Celldex Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude